Zegocractin - CalciMedica
Alternative Names: Auxora; CM-4620; CM4620-IELatest Information Update: 29 Aug 2025
At a glance
- Originator CalciMedica
- Class Anti-inflammatories; Antivirals; Benzamides; Chlorobenzenes; Dioxoles; Fluorobenzenes; Pyrazines; Small molecules; Urologics
- Mechanism of Action ORAI1 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III COVID-19 pneumonia
- Phase II Acute kidney injury; Pancreatitis; SARS-CoV-2 acute respiratory disease; Systemic inflammatory response syndrome
- Preclinical Inflammatory bowel diseases; Renal failure; Respiratory distress syndrome
Most Recent Events
- 12 Aug 2025 CalciMedica plans to meet with USFDA for Acute pancreatitis in second half of 2025
- 11 Jul 2025 Efficacy data from a phase II CARDEA trial for Covid-19 pneumonia presented at the Thrombosis Update
- 30 Oct 2024 Efficacy and adverse event data from the phase II CARPO tiral in Systemic inflammatory response syndrome and Pancreatitis released by CalciMedica